Neoadjuvant Vinorelbine–Capecitabine Versus Docetaxel–Doxorubicin–Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial (original) (raw)
Journal Article
,
Affiliations of authors: German Breast Group, Frankfurt, Germany (GvM, SL, KM); Universitäts-Frauenklinik, Essen, Germany (SK); Frauenklinik, Horst Schmidt Kliniken, Wiesbaden, Germany (PV); Frauenklinik vom Roten Kreuz, Munich, Germany (CH); Universitäts-Frauenklinik, Kiel, Germany (HE); Frauenklinik Henriettenstiftung, Hannover, Germany (J. Hilfrich); Universitäts-Frauenklinik, Rostock, Germany (BG); Universitäts-Frauenklinik, Tübingen, Germany (J. Huober); Universitäts-Frauenklinik, Magdeburg, Germany (SDC); Städtisches Klinikum Offenbach, Germany (CJ); Universitäts-Frauenklinik, Frankfurt, Germany (GvM, SL, MK)
Search for other works by this author on:
,
Affiliations of authors: German Breast Group, Frankfurt, Germany (GvM, SL, KM); Universitäts-Frauenklinik, Essen, Germany (SK); Frauenklinik, Horst Schmidt Kliniken, Wiesbaden, Germany (PV); Frauenklinik vom Roten Kreuz, Munich, Germany (CH); Universitäts-Frauenklinik, Kiel, Germany (HE); Frauenklinik Henriettenstiftung, Hannover, Germany (J. Hilfrich); Universitäts-Frauenklinik, Rostock, Germany (BG); Universitäts-Frauenklinik, Tübingen, Germany (J. Huober); Universitäts-Frauenklinik, Magdeburg, Germany (SDC); Städtisches Klinikum Offenbach, Germany (CJ); Universitäts-Frauenklinik, Frankfurt, Germany (GvM, SL, MK)
Search for other works by this author on:
,
Affiliations of authors: German Breast Group, Frankfurt, Germany (GvM, SL, KM); Universitäts-Frauenklinik, Essen, Germany (SK); Frauenklinik, Horst Schmidt Kliniken, Wiesbaden, Germany (PV); Frauenklinik vom Roten Kreuz, Munich, Germany (CH); Universitäts-Frauenklinik, Kiel, Germany (HE); Frauenklinik Henriettenstiftung, Hannover, Germany (J. Hilfrich); Universitäts-Frauenklinik, Rostock, Germany (BG); Universitäts-Frauenklinik, Tübingen, Germany (J. Huober); Universitäts-Frauenklinik, Magdeburg, Germany (SDC); Städtisches Klinikum Offenbach, Germany (CJ); Universitäts-Frauenklinik, Frankfurt, Germany (GvM, SL, MK)
Search for other works by this author on:
,
Affiliations of authors: German Breast Group, Frankfurt, Germany (GvM, SL, KM); Universitäts-Frauenklinik, Essen, Germany (SK); Frauenklinik, Horst Schmidt Kliniken, Wiesbaden, Germany (PV); Frauenklinik vom Roten Kreuz, Munich, Germany (CH); Universitäts-Frauenklinik, Kiel, Germany (HE); Frauenklinik Henriettenstiftung, Hannover, Germany (J. Hilfrich); Universitäts-Frauenklinik, Rostock, Germany (BG); Universitäts-Frauenklinik, Tübingen, Germany (J. Huober); Universitäts-Frauenklinik, Magdeburg, Germany (SDC); Städtisches Klinikum Offenbach, Germany (CJ); Universitäts-Frauenklinik, Frankfurt, Germany (GvM, SL, MK)
Search for other works by this author on:
,
Affiliations of authors: German Breast Group, Frankfurt, Germany (GvM, SL, KM); Universitäts-Frauenklinik, Essen, Germany (SK); Frauenklinik, Horst Schmidt Kliniken, Wiesbaden, Germany (PV); Frauenklinik vom Roten Kreuz, Munich, Germany (CH); Universitäts-Frauenklinik, Kiel, Germany (HE); Frauenklinik Henriettenstiftung, Hannover, Germany (J. Hilfrich); Universitäts-Frauenklinik, Rostock, Germany (BG); Universitäts-Frauenklinik, Tübingen, Germany (J. Huober); Universitäts-Frauenklinik, Magdeburg, Germany (SDC); Städtisches Klinikum Offenbach, Germany (CJ); Universitäts-Frauenklinik, Frankfurt, Germany (GvM, SL, MK)
Search for other works by this author on:
,
Affiliations of authors: German Breast Group, Frankfurt, Germany (GvM, SL, KM); Universitäts-Frauenklinik, Essen, Germany (SK); Frauenklinik, Horst Schmidt Kliniken, Wiesbaden, Germany (PV); Frauenklinik vom Roten Kreuz, Munich, Germany (CH); Universitäts-Frauenklinik, Kiel, Germany (HE); Frauenklinik Henriettenstiftung, Hannover, Germany (J. Hilfrich); Universitäts-Frauenklinik, Rostock, Germany (BG); Universitäts-Frauenklinik, Tübingen, Germany (J. Huober); Universitäts-Frauenklinik, Magdeburg, Germany (SDC); Städtisches Klinikum Offenbach, Germany (CJ); Universitäts-Frauenklinik, Frankfurt, Germany (GvM, SL, MK)
Search for other works by this author on:
,
Affiliations of authors: German Breast Group, Frankfurt, Germany (GvM, SL, KM); Universitäts-Frauenklinik, Essen, Germany (SK); Frauenklinik, Horst Schmidt Kliniken, Wiesbaden, Germany (PV); Frauenklinik vom Roten Kreuz, Munich, Germany (CH); Universitäts-Frauenklinik, Kiel, Germany (HE); Frauenklinik Henriettenstiftung, Hannover, Germany (J. Hilfrich); Universitäts-Frauenklinik, Rostock, Germany (BG); Universitäts-Frauenklinik, Tübingen, Germany (J. Huober); Universitäts-Frauenklinik, Magdeburg, Germany (SDC); Städtisches Klinikum Offenbach, Germany (CJ); Universitäts-Frauenklinik, Frankfurt, Germany (GvM, SL, MK)
Search for other works by this author on:
,
Affiliations of authors: German Breast Group, Frankfurt, Germany (GvM, SL, KM); Universitäts-Frauenklinik, Essen, Germany (SK); Frauenklinik, Horst Schmidt Kliniken, Wiesbaden, Germany (PV); Frauenklinik vom Roten Kreuz, Munich, Germany (CH); Universitäts-Frauenklinik, Kiel, Germany (HE); Frauenklinik Henriettenstiftung, Hannover, Germany (J. Hilfrich); Universitäts-Frauenklinik, Rostock, Germany (BG); Universitäts-Frauenklinik, Tübingen, Germany (J. Huober); Universitäts-Frauenklinik, Magdeburg, Germany (SDC); Städtisches Klinikum Offenbach, Germany (CJ); Universitäts-Frauenklinik, Frankfurt, Germany (GvM, SL, MK)
Search for other works by this author on:
,
Affiliations of authors: German Breast Group, Frankfurt, Germany (GvM, SL, KM); Universitäts-Frauenklinik, Essen, Germany (SK); Frauenklinik, Horst Schmidt Kliniken, Wiesbaden, Germany (PV); Frauenklinik vom Roten Kreuz, Munich, Germany (CH); Universitäts-Frauenklinik, Kiel, Germany (HE); Frauenklinik Henriettenstiftung, Hannover, Germany (J. Hilfrich); Universitäts-Frauenklinik, Rostock, Germany (BG); Universitäts-Frauenklinik, Tübingen, Germany (J. Huober); Universitäts-Frauenklinik, Magdeburg, Germany (SDC); Städtisches Klinikum Offenbach, Germany (CJ); Universitäts-Frauenklinik, Frankfurt, Germany (GvM, SL, MK)
Search for other works by this author on:
,
Affiliations of authors: German Breast Group, Frankfurt, Germany (GvM, SL, KM); Universitäts-Frauenklinik, Essen, Germany (SK); Frauenklinik, Horst Schmidt Kliniken, Wiesbaden, Germany (PV); Frauenklinik vom Roten Kreuz, Munich, Germany (CH); Universitäts-Frauenklinik, Kiel, Germany (HE); Frauenklinik Henriettenstiftung, Hannover, Germany (J. Hilfrich); Universitäts-Frauenklinik, Rostock, Germany (BG); Universitäts-Frauenklinik, Tübingen, Germany (J. Huober); Universitäts-Frauenklinik, Magdeburg, Germany (SDC); Städtisches Klinikum Offenbach, Germany (CJ); Universitäts-Frauenklinik, Frankfurt, Germany (GvM, SL, MK)
Search for other works by this author on:
Received:
24 October 2007
Revision received:
11 February 2008
Accepted:
28 February 2008
Cite
Gunter von Minckwitz, Sherko Kümmel, Petra Vogel, Claus Hanusch, Holger Eidtmann, Jörn Hilfrich, Bernd Gerber, Jens Huober, Serban Dan Costa, Christian Jackisch, Sibylle Loibl, Keyur Mehta, Manfred Kaufmann, On behalf of the German Breast Group, Neoadjuvant Vinorelbine–Capecitabine Versus Docetaxel–Doxorubicin–Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial, JNCI: Journal of the National Cancer Institute, Volume 100, Issue 8, 16 April 2008, Pages 542–551, https://doi.org/10.1093/jnci/djn085
Close
Navbar Search Filter Mobile Enter search term Search
Abstract
Background
Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome. We compared the response of nonresponding patients who continued the same treatment with that of patients who switched to a well-tolerated non–cross-resistant regimen.
Methods
Previously untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m 2 , doxorubicin at 50 mg/m 2 , and cyclophosphamide at 500 mg/m 2 per day (TAC). Patients whose tumors did not decrease in size by at least 50% were randomly assigned to four additional cycles of TAC or to four cycles of vinorelbine at 25 mg/m 2 and capecitabine at 2000 mg/m 2 (NX). The outcome was sonographic response, defined as a reduction in the product of the two largest perpendicular diameters by at least 50%. A difference of 10% or less in the sonographic response qualified as noninferiority of the NX treatment. Pathological complete response was defined as no invasive or in situ residual tumor masses in the breast and lymph nodes. Toxic effects were assessed. All statistical tests were two-sided.
Results
Of 2090 patients enrolled in the GeparTrio study, 622 (29.8%) who did not respond to two initial cycles of TAC were randomly assigned to an additional four cycles of TAC (n = 321) or to four cycles of NX (n = 301). Sonographic response rate was 50.5% for the TAC arm and 51.2% for the NX arm. The difference of 0.7% (95% confidence interval = −7.1% to 8.5%) demonstrated noninferiority of NX ( P = .008). Similar numbers of patients in both arms received breast-conserving surgery (184 [57.3%] in the TAC arm vs 180 [59.8%] in the NX arm) and had a pathological complete response (5.3% vs 6.0%). Fewer patients in the NX arm than in the TAC arm had hematologic toxic effects, mucositis, infections, and nail changes, but more had hand–foot syndrome and sensory neuropathy.
Conclusion
Pathological complete responses to both regimens were marginal. Among patients who did not respond to the initial neoadjuvant TAC treatment, similar efficacy but better tolerability was observed by switching to NX than continuing with TAC.
© The Author 2008. Published by Oxford University Press.
Topic:
- doxorubicin
- cyclophosphamide
- neoadjuvant therapy
- infections
- arm
- breast
- foot
- hematology
- lymph nodes
- neoplasms
- breast cancer
- docetaxel
- vinorelbine
- capecitabine
- sensory neuropathy
- residual tumor
- breast conserving surgery
- toxic effect
- mucositis
- complete remission
- chemotherapy, neoadjuvant
- nail changes
- unresponsive to stimuli
You do not currently have access to this article.
Personal account
- Sign in with email/username & password
- Get email alerts
- Save searches
- Purchase content
- Activate your purchase/trial code
- Add your ORCID iD
Get help with access
Institutional access
Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:
IP based access
Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.
Sign in through your institution
Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.
- Click Sign in through your institution.
- Select your institution from the list provided, which will take you to your institution's website to sign in.
- When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
- Following successful sign in, you will be returned to Oxford Academic.
If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.
Sign in with a library card
Enter your library card number to sign in. If you cannot sign in, please contact your librarian.
Society Members
Society member access to a journal is achieved in one of the following ways:
Sign in through society site
Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:
- Click Sign in through society site.
- When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
- Following successful sign in, you will be returned to Oxford Academic.
If you do not have a society account or have forgotten your username or password, please contact your society.
Sign in using a personal account
Some societies use Oxford Academic personal accounts to provide access to their members. See below.
Personal account
A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.
Some societies use Oxford Academic personal accounts to provide access to their members.
Viewing your signed in accounts
Click the account icon in the top right to:
- View your signed in personal account and access account management features.
- View the institutional accounts that are providing access.
Signed in but can't access content
Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.
Institutional account management
For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.
Purchase
Short-term Access
To purchase short-term access, please sign in to your personal account above.
Don't already have a personal account? Register
Neoadjuvant Vinorelbine–Capecitabine Versus Docetaxel–Doxorubicin–Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial - 24 Hours access
EUR €38.00
GBP £33.00
USD $41.00
Rental
This article is also available for rental through DeepDyve.
Citations
Views
Altmetric
Metrics
Total Views 6,286
3,593 Pageviews
2,693 PDF Downloads
Since 11/1/2016
Month: | Total Views: |
---|---|
November 2016 | 1 |
December 2016 | 2 |
January 2017 | 8 |
February 2017 | 13 |
March 2017 | 21 |
April 2017 | 14 |
May 2017 | 17 |
June 2017 | 20 |
July 2017 | 16 |
August 2017 | 22 |
September 2017 | 24 |
October 2017 | 10 |
November 2017 | 32 |
December 2017 | 68 |
January 2018 | 65 |
February 2018 | 84 |
March 2018 | 68 |
April 2018 | 128 |
May 2018 | 142 |
June 2018 | 125 |
July 2018 | 196 |
August 2018 | 179 |
September 2018 | 134 |
October 2018 | 120 |
November 2018 | 153 |
December 2018 | 125 |
January 2019 | 98 |
February 2019 | 84 |
March 2019 | 116 |
April 2019 | 131 |
May 2019 | 158 |
June 2019 | 156 |
July 2019 | 141 |
August 2019 | 128 |
September 2019 | 117 |
October 2019 | 87 |
November 2019 | 63 |
December 2019 | 75 |
January 2020 | 62 |
February 2020 | 61 |
March 2020 | 54 |
April 2020 | 72 |
May 2020 | 39 |
June 2020 | 66 |
July 2020 | 76 |
August 2020 | 51 |
September 2020 | 76 |
October 2020 | 52 |
November 2020 | 47 |
December 2020 | 39 |
January 2021 | 57 |
February 2021 | 23 |
March 2021 | 42 |
April 2021 | 51 |
May 2021 | 43 |
June 2021 | 39 |
July 2021 | 31 |
August 2021 | 52 |
September 2021 | 68 |
October 2021 | 61 |
November 2021 | 60 |
December 2021 | 59 |
January 2022 | 46 |
February 2022 | 53 |
March 2022 | 95 |
April 2022 | 76 |
May 2022 | 49 |
June 2022 | 71 |
July 2022 | 71 |
August 2022 | 76 |
September 2022 | 61 |
October 2022 | 64 |
November 2022 | 67 |
December 2022 | 60 |
January 2023 | 34 |
February 2023 | 35 |
March 2023 | 64 |
April 2023 | 84 |
May 2023 | 57 |
June 2023 | 39 |
July 2023 | 76 |
August 2023 | 66 |
September 2023 | 62 |
October 2023 | 56 |
November 2023 | 50 |
December 2023 | 40 |
January 2024 | 41 |
February 2024 | 46 |
March 2024 | 61 |
April 2024 | 54 |
May 2024 | 39 |
June 2024 | 37 |
July 2024 | 65 |
August 2024 | 35 |
September 2024 | 33 |
October 2024 | 1 |
Citations
225 Web of Science
×
Email alerts
Citing articles via
More from Oxford Academic